



# Supplementary Material

**Table S1.** Primers used in this study.


Primers	Sequence (5'-3' Direction)
CgT44A-F	CCTCGACACAAAGGCCAGTCITTGATGT
CgT44A-R	GCGACATCAAAGACTGGCGCCTTGTGTCG
CgP45A-F	CGACACAAAGACGGCGGTCTTGATGTCGC
CgP45A-R	GACATCAAAGACCGCCGTCTTGTCGAG
CgM216A-F	CGACATCCGACCGCGCCTGATTACTTCGT
CgM216A-R	GAAGTAATCAGGCGCGTGCAGTCGTT
CgH239A-F	TTCGACTCCGAGGCGACCGGCATGCCACAC
CgH239A-R	GTGGCATGCCGGTCGCCTCGGAGTCGAAGG
CgT240A-F	TTCGACTCCGAGCACGCCGGCATGCCACAC
CgT240A-R	GTGGCATGCCCGCGTGCCTGGAGTCGAAGG
CgG241A-F	GAATCCGAGCACCCCGATGCCACACGGT
CgG241A-R	CACCGTGTGGCATGCCGGTGTGCTCGGAGT
CgK289A-F	AGCTCACCGCATGGCGAGCAGGGCAAAG
CgK289A-R	TGGCCCTGCTGCGCCATGCCGGTGAAGCTGCG
CgQ290A-F	TCACCGCATGAAGGCCAGGGCAAAGCGG
CgQ290A-R	GCTTGGCCCTGCGCCTTCATGCCGGTGAGC
CgQ291A-F	CCGCATGAAGCAGGCCAGGGCAAAGCGGAGC
CgQ291A-R	TCCGCTTGGCCCGCCTGCTTCATGCCGGTG
CgG292A-F	CGCATGAAGCAGCAGGCCAGGGCAAAGCGGAGCT
CgG292A-R	GAAAGCTCCGCTTGCCTGCTGCTTCAT
CgL176X-F	ATCCGAAGACGCCNNKGAAAAGGCC
CgL176X-R	CCTTTCMNNGCGTCTCGGATGG
CgR180X-F	CTGGAAAAGGCNNKCCGCGGCGAAG
CgR180X-R	TCGCCGCGMNNGGCTTCCAGGG
CgH193X-F	GGAAAGCAAACCNNKAAGGCCAACCTTC
CgH193X-R	GCATTGGCGCTTMNNGGTTGCTTCGGGT
CgM216X-F	ACGACATCCGACCCNNKCTGATTACTTCG
CgM216X-R	AAGTAATCAGGMNNGGTGCAGTCGTT
CgT240X-F	TTCGACTCCGAGCACNNKCCGATGCCACAC
CgT240X-R	GTGGCATGCCMNNGGTGCAGTCGAAGG
CgK289X-F	CTCACCGCATNNKAGCAGGGCAAAGCG
CgK289X-R	CTTGCCCTGCTGMNNCATGCCGGTGAGCT
CgQ290X-F	GCTCACCGCATGAAGNNKAGGGCAAAGC
CgQ290X-R	TTTGGCCCTGMNNCTTCATGCCGGTGAGCTG



**Figure S1.** RMSD analysis of CgDAPDH and alanine mutants MD simulation trajectory.



**Figure S2.** Comparison of substrate binding energy between CgDAPDH and alanine mutants.



**Figure S3.** Specific activities of CgDAPDH and its positive mutants towards pyruvic acid: (a) Specific activity of positive mutants at site L176, R180, H193 and M216; (b) Specific activity of positive mutants at site T240, K289 and Q290. The number after the mutant's name referred to the number on the 96 deep-well plates during the screening process.